A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma (OLYMPIA-5)
Sprache der Kurzfassung:
Deutsch
Englische Bezeichnung:
A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (REGN1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma (OLYMPIA-5)